MGB Biopharma Ltd., of Glasgow, Scotland, raised $1.15 million in a financing round with existing investors. The company will use the funds to advance its lead product, MGB-BP-3, toward a phase II trial to investigate the safety and efficacy in patients with Clostridium difficile-associated disease, including disease caused by the most virulent ribotype, B1/NAP1/027.